14 citations
,
April 2020 in “Journal of Cosmetic Dermatology” In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.
7 citations
,
August 2020 in “Plastic and reconstructive surgery. Global open” In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.
4 citations
,
April 2021 in “Journal of Cosmetic Dermatology” This study found that both intradermal injection and derma roller techniques for QR678Neo® hair regrowth therapy improved androgenetic alopecia symptoms, with intradermal injections showing non-significantly better video-microscopic outcomes but more pain and erythema associated with derma rollers.